Posts Tagged ‘
Class III ’
Mar 29th, 2013 |
By Jane Akre
March 29, 2013 ~ In September 2011, the U.S. Food and Drug Administration convened a panel of experts to try and get a handle on the concerning number of complications the agency was receiving about surgical mesh used to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI). The experts suggested that because of the
[continue reading...]
Posted in FDA |
10 comments
Tags: Adverse Event, Class II, Class III, Dr. Benson, erosion, FDA, Food and Drug Administration, High-Risk Device, Linda Gross v Ethicon, MDND, Mesh medical Device News Desk, non-mesh surgery, not rare, pelvic organ prolapse, POP, premarket review, Stress urinary incontinence, SUI, SUI mesh, SUI mesh injuries, SUI repairs
Jun 20th, 2012 |
By Jane Akre
Next Wednesday, June 27 and Thursday, June 28, the U.S. Food and Drug Administration (FDA) will convene one of its expert panels – this one on patient complications after a metal-on-metal hip implant. It is a gathering called by the Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee within the FDA. The
[continue reading...]
Posted in FDA |
No Comments »
Tags: 510(k), A.S.R, acetabular component, advisory panel, Ann Morrison, BBC, birmingham Hip Resurfacing, British Medical Journal, chromium, Class II, Class III, cobalt, DePuy, FDA, Howard Sadwin, Johnson & Johnson, Medtronic, metal ions, metal-on-metal hips, MoM, recall, resurfacing system, Smight & Nephew, total hip replacements, transvaginal mesh
Jan 19th, 2012 |
By Jane Akre
January 19, 2012 ~ In a letter to the Editor of the New England Journal of Medicine (NEJM), (here) January 19, 2012, Neil Feder, M.D. of the Project on Government Oversight writes about the 510(k) process that allows untested medical devices onto the market without premarket approval. Share this:
Posted in Medical News |
1 Comment »
Tags: 510(k), ASR hip, Class II medical device, Class III, DePuy, FDA, Institute of Medicine, Johnson & Johnson, Medical devices, metal on metal hip, New England Journal of Medicine, recall, substantial equivalence
Jan 12th, 2012 |
By Jane Akre
JANUARY 12, 2012 ~ A growing number of women from around the country who are plaintiffs in transvaginal mesh litigation have a court date of Wednesday, January 26 in Miami. The Judicial Panel on Multidistrict Litigation (MDL) is set to hear requests by plaintiff attorneys to have thousands of defective mesh lawsuits consolidated in the
[continue reading...]
Posted in Legal News |
2 comments
Tags: American Medical Systems, Bard Avaulta mesh, Boston Scientific, Class II, Class III, Ethicon, FDA, Food and Drug Administration, Incontinence, infection, Johnson & Johnson, Judge Joseph R. Goodwin, Judicial Panel on Multidistrict Litigation, MDL, medical device, mesh complications, mesh erosion, mesh injuries, mesh migration, Multidistrict Litigation, not rare, pelvic organ prolapse, product liability litigation, transvaginal mesh
Sep 13th, 2011 |
By Jane Akre
MedPage Today (here) reports an FDA advisory panel meeting over synthetic mesh used to treat stress urinary incontinence (SUI) said it would like more scientific data on the newer generation of devices but recommended leaving in place the 510(k) approval process. FDA Panel Listens to Industry, Patients, Staff The Obstetrics and Gynecology Devices panel issued
[continue reading...]
Posted in Media Reports |
No Comments »
Tags: Benefit, Class II, Class III, high-risk, Incontinence, MAUDE, mesh, pelvic floor problems, POP, Risk, SUI
Aug 25th, 2011 |
By Jane Akre
AUGUST 25, 2011 – Synthetic surgical mesh is implanted into women for the treatment of pelvic organ prolapse and incontinence and now Public Citizen is calling for a ban citing the needless exposure of patients to serious, life-altering complications. Synthetic mesh used for pelvic surgeries, and hernia repair in men, is made of a petroleum-based
[continue reading...]
Posted in Feature |
No Comments »
Tags: 510(k), Class III, FDA, non-absorbable mesh, petition, POP, Public Citizen, SUI, Transvaginally
Aug 15th, 2011 |
By Jane Akre
This excellent article by Morningstar reminds us that the Food and Drug Administration (FDA) has been reviewing the regulatory process that allows most medical devices to make their way into the marketplace and the agency plans to have new changes in place by October. This is sparked by the July release of the Institute of
[continue reading...]
Posted in FDA, Media Reports |
No Comments »
Tags: Class III, high-risk, Institute of Medicine, IOM, medical device industry, Morningstar, Stryker, substantially equivalent, Zimmer